Table 3.

Patient characteristics associated with recall of medication dose and frequency.

Characteristic	Recall dose	P	Recall frequency	P	Recall both(dose + frequency)	P
Aminosalicylates (n =74 on drug)	n = 49		n = 52		n = 45
Female	33 (67%)	0.53	35 (67%)	0.50	31 (69%)	0.37
Crohn’s disease	18 (37%)	0.78	20 (38%)	0.86	17 (38%)	0.99
Pediatric onset (diagnosis at < 18y old)	6 (12%)	0.72	8 (15%)	0.71	5 (11%)	0.49
Disease duration (years since diagnosis)	9.0 (4.5, 14.5)	0.97	10.5 (4.5, 16.0)	0.36	9.0 (5.0, 15.0)	0.88
Immunomodulators (n=41 on drug)	n = 31		n = 34		n = 30
Female	16 (52%)	0.15	20 (59%)	1.00	16 (53%)	0.31
Crohn’s disease	13 (42%)	0.72	13 (38%)	0.21	12 (40%)	0.49
Pediatric onset (diagnosis at < 18y old)	9 (29%)	1.00	8 (24%)	0.17	8 (27%)	0.70
Disease duration (years since diagnosis)	8.5 (6.0, 15.0)	0.79	8.0 (6.0, 15.0)	0.24	8.0 (6.0, 16.0)	0.69
Biologics (n = 48 on drug)	n = 33		n = 31		n = 26
Female	15 (45%)	0.03	15 (48%)	0.14	12 (46%)	0.13
Crohn’s disease	26 (79%)	0.29	23 (74%)	1.00	20 (77%)	0.50
Pediatric onset (diagnosis at < 18y old)	10 (32%)	0.28	11 (38%)	0.03	9 (38%)	0.07
Disease duration (years since diagnosis)	9.0 (6.0, 19.0)	0.10	9.0 (6.0, 17.0)	0.38	9.0 (7.0, 19.0)	0.25

P-value from Pearson chi-square test, Fisher exact test, or Wilcoxon rank-sum test. Age at diagnosis is unknown for 2 patients, and disease duration is unknown for 12 patients.